HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
June 16, 2024 20:00 ET
|
HUTCHMED (China) Limited
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of...
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024 06:10 ET
|
Regeneron Pharmaceuticals, Inc.
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously...
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
June 16, 2024 05:30 ET
|
Nurix Therapeutics, Inc.
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
ROSEN, A LEADING LAW FIRM, Encourages CI&T Inc Investors to Inquire About Securities Class Action Investigation – CINT
June 15, 2024 13:09 ET
|
The Rosen Law Firm PA
NEW YORK, June 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of CI&T Inc...
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
June 15, 2024 08:45 ET
|
Agios Pharmaceuticals, Inc.
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights...
CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law about Ongoing Investigation into the Deal Price
June 15, 2024 06:37 ET
|
Bleichmar Fonti & Auld
Cerevel Shareholders are encouraged to contact BFA Law firm about their rights relating to the upcoming merger.
Global Companion Diagnostics Market Size To Exceed USD 23.12 Billion By 2033 | CAGR Of 12.50%
June 15, 2024 02:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 15, 2024 (GLOBE NEWSWIRE) -- The Global Companion Diagnostics Market Size is to Grow from USD 7.12 Billion in 2023 to USD 23.12 Billion by 2033, at a CAGR of 12.50%...
Global Mammography Chairs Market Size To Exceed USD 140.5 Million By 2033 | CAGR of 5.86%
June 15, 2024 01:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 15, 2024 (GLOBE NEWSWIRE) -- The Global Mammography Chairs Market Size is to Grow from USD 79.5 Million in 2023 to USD 140.5 Million By 2033, at a Compound Annual...
Global Dermal Toxicity Testing Market Size To Exceed USD 4.95 Billion By 2033 | CAGR of 8.11%
June 14, 2024 22:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 14, 2024 (GLOBE NEWSWIRE) -- The Global Dermal Toxicity Testing Market Size is to Grow from USD 2.27 Billion in 2023 to USD 4.95 Billion By 2033, at a Compound Annual...
Global Laboratory Proficiency Testing Market Size To Exceed USD 2.62 Billion By 2033 | CAGR Of 7.18%
June 14, 2024 21:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 14, 2024 (GLOBE NEWSWIRE) -- The Global Laboratory Proficiency Testing Market Size is to Grow from USD 1.31 Billion in 2023 to USD 2.62 Billion by 2033, at a CAGR of...